121. Improving Predictive Value of Phase 2a TB Drug Development Models through PET/CT Imaging (NexGen EBA)
Session: Oral Abstract Session: Tuberculosis and other Mycobacterial Infections
Thursday, October 4, 2018: 9:15 AM
Room: W 2002


Current Phase 2a methods in tuberculosis (TB) drug development are severely limited in capturing a drug candidate’s sterilizing activity (ability to prevent TB relapse). We hypothesize that sputum-based measurements of current methods fail to capture drug activity in deep TB lesion compartments, where recalcitrant TB populations are sequestered. In our recent marmoset study, we found complementary 14-day PET/CT delta signatures across different TB lesion compartments that distinguish drugs with long-term sterilizing activity (e.g. rifampin and pyrazinamide) versus drugs with primarily early bactericidal activity (e.g. isoniazid) (Fig. 1). We proceeded to evaluate this novel PET/CT Phase 2a approach among TB patients, benchmarked by drugs that are well-characterized clinically and pharmacokinetically.


HIV-negative patients with smear-positive pulmonary tuberculosis from Cape Town, South Africa were enrolled and randomized to receive a single drug [isoniazid (H), rifampin (R), pyrazinamide (Z), moxifloxacin (M)], a 2-drug regimen (HZ, RZ), or a 4-drug regimen (HRZE, MRZE) for 14 days in an inpatient facility. Primary data points were PET/CT scans evaluated at pre-treatment baseline and treatment day 14 (and day 28 in the HRZE arm), and daily overnight sputum for early bactericidal activity measurements.


From December 2015 to September 2017, 160 participants completed the study, from whom 340 PET/CT scans and 2238 overnight sputum samples were collected.  PET/CT scans from participants demonstrate diversity of lesion architecture and inter-individual variation in PET/CT changes over 14 days of treatment (Fig. 2). A preliminary computational algorithm and 1st and 2nd order PET/CT statistics have been developed for initial segmentation and TB lesion categorization of all study scans. Derivation of radiologic signatures by analysis of 14-day PET/CT changes across each lesion type is ongoing; blinded prediction of each participant’s treatment arm based on these signatures is expected by third quarter 2018.


If successful, these signatures may be applied within a 14-day Phase 2a framework to evaluate new TB drug candidates and construct TB drug regimens with complementary lesion pharmacokinetics.

Yingda Xie, MD1, Laura Via, Ph.D1, Ray Chen, MD1, Lori Dodd, Ph.D.2, Ying Cai, MS1, Paveen Paripati, MS3, Lisa Goldfeder, CCRP4, Jill Winter, PhD5, Kriti Arora, PhD1, Jing Wang, PhD2, Veronique De Jagar, MD6, Stephanus Malherbe, MD, PhD7, Taeksun Song, Ph.D8, Gerhard Walzl, PhD7, Andreas Diacon, MD, PhD9 and Clifton Barry III, Ph.D1, (1)Tuberculosis Research Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, (2)Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, (3)NET ESOLUTIONS/Figure Ground Innovations LLC., McLean, VA, (4)Office of Research Support and Compliance, National Institutes of Health, Bethesda, MD, (5)Catalysis Foundation for Health, Emeryville, CA, (6)Task Applied Sciences, Cape Town, South Africa, (7)Stellenbosch University, Stellenbosch, South Africa, (8)University of Cape Town, Cape Town, South Africa, (9)Task Applied Science, Cape Town, South Africa


Y. Xie, None

L. Via, None

R. Chen, None

L. Dodd, None

Y. Cai, None

P. Paripati, None

L. Goldfeder, None

J. Winter, None

K. Arora, None

J. Wang, None

V. De Jagar, None

S. Malherbe, None

T. Song, None

G. Walzl, None

A. Diacon, None

C. Barry III, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.